Verve Therapeutics Inc.

3.85
-0.06 (-1.53%)
At close: Apr 03, 2025, 3:59 PM
3.75
-2.47%
After-hours: Apr 03, 2025, 05:09 PM EDT

Verve Therapeutics Statistics

Share Statistics

Verve Therapeutics has 88.8M shares outstanding. The number of shares has increased by 5.75% in one year.

Shares Outstanding 88.8M
Shares Change (YoY) 5.75%
Shares Change (QoQ) 4.88%
Owned by Institutions (%) 93.39%
Shares Floating 66.18M
Failed to Deliver (FTD) Shares 225
FTD / Avg. Volume 0.02%

Short Selling Information

The latest short interest is 14.79M, so 17.47% of the outstanding shares have been sold short.

Short Interest 14.79M
Short % of Shares Out 17.47%
Short % of Float 23.43%
Short Ratio (days to cover) 10.17

Valuation Ratios

The PE ratio is -2.39 and the forward PE ratio is -2.61. Verve Therapeutics's PEG ratio is 0.1.

PE Ratio -2.39
Forward PE -2.61
PS Ratio 14.69
Forward PS 17.3
PB Ratio 0.96
P/FCF Ratio -2.94
PEG Ratio 0.1
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Verve Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 12.65, with a Debt / Equity ratio of 0.14.

Current Ratio 12.65
Quick Ratio 12.65
Debt / Equity 0.14
Debt / EBITDA -0.31
Debt / FCF -0.43
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $118K
Profits Per Employee $-725.22K
Employee Count 274
Asset Turnover 0.05
Inventory Turnover n/a

Taxes

Income Tax 349K
Effective Tax Rate -0.18%

Stock Price Statistics

The stock price has increased by -55.8% in the last 52 weeks. The beta is 1.78, so Verve Therapeutics's price volatility has been higher than the market average.

Beta 1.78
52-Week Price Change -55.8%
50-Day Moving Average 6.77
200-Day Moving Average 5.97
Relative Strength Index (RSI) 24.87
Average Volume (20 Days) 1.46M

Income Statement

In the last 12 months, Verve Therapeutics had revenue of 32.33M and earned -198.71M in profits. Earnings per share was -2.36.

Revenue 32.33M
Gross Profit 32.33M
Operating Income -228.66M
Net Income -198.71M
EBITDA -228.66M
EBIT -228.66M
Earnings Per Share (EPS) -2.36
Full Income Statement

Balance Sheet

The company has 172.56M in cash and 69.98M in debt, giving a net cash position of 102.58M.

Cash & Cash Equivalents 172.56M
Total Debt 69.98M
Net Cash 102.58M
Retained Earnings -743.01M
Total Assets 647.39M
Working Capital 499.84M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -157.69M and capital expenditures -3.74M, giving a free cash flow of -161.43M.

Operating Cash Flow -157.69M
Capital Expenditures -3.74M
Free Cash Flow -161.43M
FCF Per Share -1.92
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -707.23% and -614.59%.

Gross Margin 100%
Operating Margin -707.23%
Pretax Margin -613.51%
Profit Margin -614.59%
EBITDA Margin -707.23%
EBIT Margin -707.23%
FCF Margin -499.28%

Dividends & Yields

VERV does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for VERV is $23.5, which is 510.4% higher than the current price. The consensus rating is "Buy".

Price Target $23.5
Price Target Difference 510.4%
Analyst Consensus Buy
Analyst Count 5
Stock Forecasts

Scores

Altman Z-Score -0.34
Piotroski F-Score 3